Skip to content
10-Q

Quarterly Report

Omega Therapeutics, Inc.

0000950170-24-053198

← back to feed
Filed
May 6, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 2, 2024 55.15M sh
Shares Diluted Q1 2024 · Mar 31, 2024 55.15M sh
Shares Diluted Q1 2024 · Mar 31, 2023 50.63M sh
Capex Q1 2024 · Mar 31, 2024 $535K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$11.81M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$28.11M
Long Term Debt Q1 2024 · Mar 31, 2024 $13.9M
Long Term Debt Q1 2024 · Dec 31, 2023 $14.89M
Short Term Debt Q1 2024 · Mar 31, 2024 $4M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $60.03M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $68.44M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $104.54M
Stockholders Equity Q1 2024 · Mar 31, 2024 $41.35M
Stockholders Equity Q1 2024 · Dec 31, 2023 $58.02M
Stockholders Equity Q1 2024 · Mar 31, 2023 $123M
Stockholders Equity Q1 2024 · Dec 31, 2022 $105.97M
Current Liabilities Q1 2024 · Mar 31, 2024 $24.68M
Current Liabilities Q1 2024 · Dec 31, 2023 $26.81M
Total Liabilities Q1 2024 · Mar 31, 2024 $142.33M
Total Liabilities Q1 2024 · Dec 31, 2023 $146.35M
Current Assets Q1 2024 · Mar 31, 2024 $70.89M
Current Assets Q1 2024 · Dec 31, 2023 $89.88M
Total Assets Q1 2024 · Mar 31, 2024 $183.68M
Total Assets Q1 2024 · Dec 31, 2023 $204.37M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.36
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.50
Eps Basic Q1 2024 · Mar 31, 2024 −$0.36
Eps Basic Q1 2024 · Mar 31, 2023 −$0.50
Sga Expense Q1 2024 · Mar 31, 2024 $7.4M
Sga Expense restated Q1 2024 · Mar 31, 2023 $6.24M
Rd Expense Q1 2024 · Mar 31, 2024 $15.42M
Rd Expense restated Q1 2024 · Mar 31, 2023 $20.09M
Net Income Q1 2024 · Mar 31, 2024 −$20.13M
Net Income Q1 2024 · Mar 31, 2023 −$25.28M
Operating Income Q1 2024 · Mar 31, 2024 −$20.45M
Operating Income Q1 2024 · Mar 31, 2023 −$25.82M